CYT 1853
Alternative Names: CYT-1853Latest Information Update: 10 May 2024
At a glance
- Originator Cyteir Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Rad51 recombinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 20 Mar 2024 Cyteir Therapeutics winds down its business and remains no longer active (Cyteir Therapeutic pipeline, May 2024)
- 08 May 2023 Discontinued - Preclinical for Haematological malignancies in USA (unspecified route)
- 08 May 2023 Discontinued - Preclinical for Solid tumours in USA (unspecified route)